PAVmed (PAVM) Net Equity Issued and Repurchased (2019 - 2025)

PAVmed has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $1.6 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 399.09% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $2.5 million, a 48.01% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 55.69% from the prior year.
• Net Equity Issued and Repurchased was $1.6 million for Q4 2025 at PAVmed, up from -$1.6 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $55.0 million in Q1 2021, with the low at -$1.6 million in Q3 2025.
• Average Net Equity Issued and Repurchased over 5 years is $4.3 million, with a median of $462000.0 recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased soared 43563.49% in 2021, then plunged 99.6% in 2022.
• Over 5 years, Net Equity Issued and Repurchased stood at $131000.0 in 2021, then tumbled by 146.56% to -$61000.0 in 2022, then jumped by 701.64% to $367000.0 in 2023, then retreated by 10.08% to $330000.0 in 2024, then jumped by 399.09% to $1.6 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $1.6 million (Q4 2025), -$1.6 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.